Business Description
Embla Medical hf
ISIN : IS0000000040
Total Employee Number:
4,500Compare
Compare
Traded in other countries / regions
EMBLA.Denmark5IQ.Germany0FIW.UKOSSUY.USA IPO Date
2025-08-04Description
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | 2.87 | |||||
Interest Coverage | 6.05 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.87 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.7 | |||||
3-Year EBITDA Growth Rate | 12.7 | |||||
3-Year EPS without NRI Growth Rate | 20 | |||||
3-Year FCF Growth Rate | 36.8 | |||||
3-Year Book Growth Rate | 7.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.96 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.69 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.37 | |||||
9-Day RSI | 52.95 | |||||
14-Day RSI | 51.82 | |||||
3-1 Month Momentum % | -2.54 | |||||
6-1 Month Momentum % | -19.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 164.6 | |||||
Days Sales Outstanding | 54.28 | |||||
Days Payable | 34.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | 1.45 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.97 | |||||
Operating Margin % | 13.09 | |||||
Net Margin % | 8.93 | |||||
EBITDA Margin % | 20.25 | |||||
FCF Margin % | 10.02 | |||||
OCF Margin % | 13.32 | |||||
ROE % | 9.84 | |||||
ROA % | 5 | |||||
ROIC % | 6.24 | |||||
3-Year ROIIC % | 16.55 | |||||
ROC (Joel Greenblatt) % | 33.52 | |||||
ROCE % | 9.29 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.46 | |||||
Forward PE Ratio | 18.27 | |||||
PE Ratio without NRI | 20.46 | |||||
Shiller PE Ratio | 22.56 | |||||
Price-to-Owner-Earnings | 16.23 | |||||
PEG Ratio | 1.39 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 1.95 | |||||
Price-to-Free-Cash-Flow | 18.25 | |||||
Price-to-Operating-Cash-Flow | 13.73 | |||||
EV-to-EBIT | 16.95 | |||||
EV-to-EBITDA | 11.51 | |||||
EV-to-Revenue | 2.33 | |||||
EV-to-FCF | 23.26 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Projected-FCF | 1.08 | |||||
Price-to-DCF (Earnings Based) | 1.29 | |||||
Price-to-DCF (FCF Based) | 1.01 | |||||
Price-to-Median-PS-Value | 0.55 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.76 | |||||
Earnings Yield (Greenblatt) % | 5.9 | |||||
FCF Yield % | 5.46 | |||||
Forward Rate of Return (Yacktman) % | 15.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Embla Medical hf Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 823.491 | ||
| EPS (TTM) (€) | 0.173 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 51.82 | ||
| 14-Day ATR (€) | 0.084746 | ||
| 20-Day SMA (€) | 3.57275 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.37 - 5.04 | ||
| Shares Outstanding (Mil) | 425.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Embla Medical hf Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Embla Medical hf Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-20 | In 97 days | ||
| Third quarter earnings results for 2026 | 2026-10-20 | In 97 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-21 | In 6 days | ||
| Second quarter earnings results for 2026 | 2026-07-21 | In 6 days | ||
| First quarter earnings conference call for 2026 | 2026-04-28 09:00 | 3.60 (-1.37%) | ||
| First quarter earnings results for 2026 | 2026-04-28 07:00 | 3.60 (-1.37%) | ||
| General meeting for 2026 | 2026-03-10 09:00 | 3.84 (-0.78%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-03 09:00 | 4.14 (-0.24%) | ||
| Annual report for 2025 | 2026-02-03 07:00 | 4.14 (-0.24%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-03 07:00 | 4.14 (-0.24%) |
Show
Entries
Embla Medical hf Frequently Asked Questions
What is Embla Medical hf(FRA:5IQ)'s stock price today?
The current price of FRA:5IQ is €3.60. The 52 week high of FRA:5IQ is €5.04 and 52 week low is €3.37.
When is next earnings date of Embla Medical hf(FRA:5IQ)?
The next earnings date of Embla Medical hf(FRA:5IQ) is 2026-07-21.
Does Embla Medical hf(FRA:5IQ) pay dividends? If so, how much?
Embla Medical hf(FRA:5IQ) does not pay dividend.
Press Release
Articles on Embla Medical hf
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers